Literature DB >> 20065030

Natural variability of in vitro adherence to fibrinogen and fibronectin does not correlate with in vivo infectivity of Staphylococcus aureus.

Mathilde Ythier1, Jose M Entenza, Jacques Bille, François Vandenesch, Michèle Bes, Philippe Moreillon, Olga Sakwinska.   

Abstract

Adherence to fibrinogen and fibronectin plays a crucial role in Staphylococcus aureus experimental endocarditis. Previous genetic studies have shown that infection and carriage isolates do not systematically differ in their virulence-related genes, including genes conferring adherence, such as clfA and fnbA. We set out to determine the range of adherence phenotypes in carriage isolates of S. aureus, to compare the adherence of these isolates to the adherence of infection isolates, and to determine the relationship between adherence and infectivity in a rat model of experimental endocarditis. A total of 133 healthy carriage isolates were screened for in vitro adherence to fibrinogen and fibronectin, and 30 isolates were randomly chosen for further investigation. These 30 isolates were compared to 30 infective endocarditis isolates and 30 blood culture isolates. The infectivities of the carriage isolates, which displayed either extremely low or high adherence to fibrinogen and fibronectin, were tested using a rat model of experimental endocarditis. The levels of adherence to both fibrinogen and fibronectin were very similar for isolates from healthy carriers and members of the two groups of infection isolates. All three groups of isolates showed a wide range of adherence to fibrinogen and fibronectin. Moreover, the carriage isolates that showed minimal adherence and the carriage isolates that showed strong adherence had the same infectivity in experimental endocarditis. Adherence was proven to be important for pathogenesis in experimental endocarditis, but even the least adherent carriage strains had the ability to induce infection. We discuss the roles of differential gene expression, human host factors, and gene redundancy in resolving this apparent paradox.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20065030      PMCID: PMC2849403          DOI: 10.1128/IAI.01274-09

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  48 in total

1.  The relation between the nasal-staphylococcal-carrier state and the incidence of postoperative complications.

Authors:  H J WEINSTEIN
Journal:  N Engl J Med       Date:  1959-06-25       Impact factor: 91.245

2.  Levofloxacin versus ciprofloxacin, flucloxacillin, or vancomycin for treatment of experimental endocarditis due to methicillin-susceptible or -resistant Staphylococcus aureus.

Authors:  J M Entenza; J Vouillamoz; M P Glauser; P Moreillon
Journal:  Antimicrob Agents Chemother       Date:  1997-08       Impact factor: 5.191

3.  Expression of Staphylococcus aureus clumping factor A in Lactococcus lactis subsp. cremoris using a new shuttle vector.

Authors:  Y A Que; J A Haefliger; P Francioli; P Moreillon
Journal:  Infect Immun       Date:  2000-06       Impact factor: 3.441

4.  Population-based study of the epidemiology of and the risk factors for invasive Staphylococcus aureus infections.

Authors:  Kevin B Laupland; Deirdre L Church; Melissa Mucenski; Lloyd R Sutherland; H Dele Davies
Journal:  J Infect Dis       Date:  2003-04-15       Impact factor: 5.226

5.  Clumping factor B (ClfB), a new surface-located fibrinogen-binding adhesin of Staphylococcus aureus.

Authors:  D Ní Eidhin; S Perkins; P Francois; P Vaudaux; M Höök; T J Foster
Journal:  Mol Microbiol       Date:  1998-10       Impact factor: 3.501

6.  Changing profile of infective endocarditis: results of a 1-year survey in France.

Authors:  Bruno Hoen; François Alla; Christine Selton-Suty; Isabelle Béguinot; Anne Bouvet; Serge Briançon; Jean-Paul Casalta; Nicolas Danchin; François Delahaye; Jerome Etienne; Vincent Le Moing; Catherine Leport; Jean-Luc Mainardi; Raymond Ruimy; François Vandenesch
Journal:  JAMA       Date:  2002-07-03       Impact factor: 56.272

7.  Disparity in the in vitro versus in vivo regulation of fibronectin-binding proteins by 2 global regulators, saeRS and sigB, in Staphylococcus aureus.

Authors:  Ambrose L Cheung; Soo-Jin Yang; Arnold S Bayer; Yan Q Xiong
Journal:  J Infect Dis       Date:  2009-11-01       Impact factor: 5.226

8.  Reconsideration of the role of fibronectin binding in endocarditis caused by Staphylococcus aureus.

Authors:  J I Flock; S A Hienz; A Heimdahl; T Schennings
Journal:  Infect Immun       Date:  1996-05       Impact factor: 3.441

9.  Impacts of sarA and agr in Staphylococcus aureus strain Newman on fibronectin-binding protein A gene expression and fibronectin adherence capacity in vitro and in experimental infective endocarditis.

Authors:  Yan-Qiong Xiong; Arnold S Bayer; Michael R Yeaman; Willem Van Wamel; Adhar C Manna; Ambrose L Cheung
Journal:  Infect Immun       Date:  2004-03       Impact factor: 3.441

10.  Synthesis of staphylococcal virulence factors is controlled by a regulatory RNA molecule.

Authors:  R P Novick; H F Ross; S J Projan; J Kornblum; B Kreiswirth; S Moghazeh
Journal:  EMBO J       Date:  1993-10       Impact factor: 11.598

View more
  9 in total

1.  Combinatorial phenotypic signatures distinguish persistent from resolving methicillin-resistant Staphylococcus aureus bacteremia isolates.

Authors:  Kati Seidl; Arnold S Bayer; Vance G Fowler; James A McKinnell; Wessam Abdel Hady; George Sakoulas; Michael R Yeaman; Yan Q Xiong
Journal:  Antimicrob Agents Chemother       Date:  2010-11-22       Impact factor: 5.191

2.  The ArlRS two-component system is a regulator of Staphylococcus aureus-induced endothelial cell damage.

Authors:  Kati Seidl; Michèle Leemann; Annelies S Zinkernagel
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2017-11-27       Impact factor: 3.267

Review 3.  Infective endocarditis.

Authors:  Yok-Ai Que; Philippe Moreillon
Journal:  Nat Rev Cardiol       Date:  2011-04-12       Impact factor: 32.419

4.  Use of a human-like low-grade bacteremia model of experimental endocarditis to study the role of Staphylococcus aureus adhesins and platelet aggregation in early endocarditis.

Authors:  Tiago Rafael Veloso; Aziz Chaouch; Thierry Roger; Marlyse Giddey; Jacques Vouillamoz; Paul Majcherczyk; Yok-Ai Que; Valentin Rousson; Philippe Moreillon; José Manuel Entenza
Journal:  Infect Immun       Date:  2012-12-17       Impact factor: 3.441

5.  Proteomic and transcriptomic profiling of Staphylococcus aureus surface LPXTG-proteins: correlation with agr genotypes and adherence phenotypes.

Authors:  Mathilde Ythier; Grégory Resch; Patrice Waridel; Alexandre Panchaud; Aurélie Gfeller; Paul Majcherczyk; Manfredo Quadroni; Philippe Moreillon
Journal:  Mol Cell Proteomics       Date:  2012-07-25       Impact factor: 5.911

Review 6.  Staphylococcal superantigens interact with multiple host receptors to cause serious diseases.

Authors:  Christopher S Stach; Alfa Herrera; Patrick M Schlievert
Journal:  Immunol Res       Date:  2014-08       Impact factor: 2.829

7.  Occurrence of genes of putative fibrinogen binding proteins and hemolysins, as well as of their phenotypic correlates in isolates of S. lugdunensis of different origins.

Authors:  Florian Szabados; Yasmina Nowotny; Lennart Marlinghaus; Miriam Korte; Sandra Neumann; Martin Kaase; Sören G Gatermann
Journal:  BMC Res Notes       Date:  2011-04-08

8.  Impact of sub-inhibitory antibiotics on fibronectin-mediated host cell adhesion and invasion by Staphylococcus aureus.

Authors:  Jean Philippe Rasigade; Abdelmalek Moulay; Yannick Lhoste; Anne Tristan; Michele Bes; François Vandenesch; Jerome Etienne; Gerard Lina; Frederic Laurent; Oana Dumitrescu
Journal:  BMC Microbiol       Date:  2011-12-14       Impact factor: 3.605

9.  Human-to-bovine jump of Staphylococcus aureus CC8 is associated with the loss of a β-hemolysin converting prophage and the acquisition of a new staphylococcal cassette chromosome.

Authors:  Grégory Resch; Patrice François; Delphine Morisset; Milos Stojanov; Eve J Bonetti; Jacques Schrenzel; Olga Sakwinska; Philippe Moreillon
Journal:  PLoS One       Date:  2013-03-11       Impact factor: 3.240

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.